Cause of death in patients with less than 5% hematogones
| Primary disease . | Cause of death, no. (%) . | |||||
|---|---|---|---|---|---|---|
| Relapse of primary disease . | Transplantation-related mortality . | |||||
| Infection . | Acute GVHD (Grade II-IV) . | Total . | Infection . | Acute GVHD (Grade II-IV) . | Total . | |
| AML and advanced MDS | 14/33 (42.4) | 14/33 (42.4) | 15/33 (45.4) | 2/33 (6.1) | 0/33 (0) | 2/33 (6.1) |
| ALL | 3/9 (33.3) | 3/9 (33.3) | 3/9 (33.3) | 1/9 (11.1) | 1/9 (11.1) | 2/9 (22.2) |
| Lymphoma | 7/23 (30.4) | 7/23 (30.4) | 8/23 (34.8) | 1/23 (4.3) | 1/23 (4.3) | 2/23 (8.7) |
| Total | 24/65 (36.9) | 24/65 (36.9) | 26/65 (40) | 4/65 (6.2) | 2/65 (3.1) | 6/65 (9.2) |
| Primary disease . | Cause of death, no. (%) . | |||||
|---|---|---|---|---|---|---|
| Relapse of primary disease . | Transplantation-related mortality . | |||||
| Infection . | Acute GVHD (Grade II-IV) . | Total . | Infection . | Acute GVHD (Grade II-IV) . | Total . | |
| AML and advanced MDS | 14/33 (42.4) | 14/33 (42.4) | 15/33 (45.4) | 2/33 (6.1) | 0/33 (0) | 2/33 (6.1) |
| ALL | 3/9 (33.3) | 3/9 (33.3) | 3/9 (33.3) | 1/9 (11.1) | 1/9 (11.1) | 2/9 (22.2) |
| Lymphoma | 7/23 (30.4) | 7/23 (30.4) | 8/23 (34.8) | 1/23 (4.3) | 1/23 (4.3) | 2/23 (8.7) |
| Total | 24/65 (36.9) | 24/65 (36.9) | 26/65 (40) | 4/65 (6.2) | 2/65 (3.1) | 6/65 (9.2) |
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; GVHD, graft-versus-host disease; and MDS, myelodysplastic syndrome.